RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
CAVO M
Collezione AOU Città della Salute di Torino
Items : 102
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2025 Apr;36(4):361-374. doi: 10.1016/j.annonc.2025.01.022. Epub 2025 Feb 7.
2025
AOU Città della Salute di Torino
Musto P; Engelhardt M; van de Donk NWCJ; Gay F; Terpos E; Einsele H; Fernández de Larrea C; Sgherza N; Bolli N; Katodritou E; Gentile M; Royer B; Derudas D; Jelinek T; Zamagni E; Rosiñol L; Paiva B; Caers J; Kaiser M; Beksac M; Hájek R; Spencer A; Ludwig H; Cavo M; Bladé J; Moreau P; Mateos MV; San-Miguel JF; Dimopoulos MA; et alii...
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study. in Cancer medicine / Cancer Med. 2024 Nov;13(22):e70266. doi: 10.1002/cam4.70266.
2024
AOU Città della Salute di Torino
Mancuso K; Mina R; Rocchi S; Antonioli E; Petrucci MT; Fazio F; Gozzetti A; Salvini M; Cartia CS; Bertuglia G; Patriarca F; Dalla Palma AB; Barbato S; De Cicco G; Bigi F; Favero E; Tacchetti P; Pantani L; Rizzello I; Puppi M; Talarico M; Solli V; Kanapari A; Cavo M; Zamagni E;
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3.
2024
AOU Città della Salute di Torino
Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; et alii...
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. in Leukemia / Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7.
2024
AOU Città della Salute di Torino
Hillengass J; Dimopoulos MA; Scheid C; Boccadoro M; Müller-Tidow C; Graeven U; Hänel M; von Metzler I; van der Holt B; Reimer P; Fenk R; Besemer B; Dürig J; Blau IW; Beksac M; Brossart P; Mancuso K; Pantani L; Munder M; Raab MS; Zweegman S; Salwender HJ; Hielscher T; Bertsch U; Mai EK; Weisel KC; Cavo M; Sonneveld P; Goldschmidt H; et alii...
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. in Haematologica / Haematologica. 2024 Jul 1;109(7):2337-2340. doi: 10.3324/haematol.2023.284694.
2024
AOU Città della Salute di Torino
Mateos MV; Weisel K; Terpos E; Delimpasi S; Kastritis E; Zamagni E; Delforge M; Ocio E; Katodritou E; Gay F; Larocca A; Leleu X; Otero PR; Schjesvold F; Cavo M; Dimopoulos MA;
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
2024
AOU Città della Salute di Torino
Moreau P; Bladé J; Rodriguez-Otero P; Carson R; de Boer CJ; Sitthi-Amorn A; Vanquickelberghe V; van Brummelen EMJ; Vieyra D; Wang J; Liu Y; Ahmadi T; Lonergan S; Jurczyszyn A; Hajek R; Spencer A; Einsele H; Vangsted A; Silzle T; Roeloffzen W; Delforge M; Rosiñol L; Sureda Balari A; Schjesvold F; Katodritou E; van de Donk NWCJ; Nijhof IS; Mina R; Gay F; et alii...
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study. in Cancer / Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30.
2024
AOU Città della Salute di Torino
Pane F; Bocchia M; Cilloni D; Lemoli RM; Cattaneo D; Tosoni L; Scalzulli E; Moioli A; Duminuco A; Fontana G; Loffredo M; Dedola A; Venturi M; Guglielmana V; Bosi C; Isidori A; Iurlo A; Abruzzese E; Cavazzini F; Binotto G; Crugnola M; Tieghi A; Pugliese N; Caocci G; Martino B; Farina M; Bonifacio M; Beggiato E; Tiribelli M; et alii...
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. in Cancer / Cancer. 2024 Apr 15;130(8):1270-1280. doi: 10.1002/cncr.35156. Epub 2023 Dec 28.
2024
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Breccia M; Cavo M; Bonifacio M; Vianelli N; Trawinska MM; Cuneo A; Cilloni D; Semenzato G; Lemoli RM; Pane F; Krampera M; Cattaneo D; Isidori A; Duminuco A; Venturi M; Scaffidi L; Pugliese N; Martino B; Bocchia M; Crugnola M; Bosi C; Beggiato E; Miglino M; Branzanti F; Binotto G; Cavazzini F; Caocci G; Tieghi A; Auteri G; et alii...
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. in Future oncology (London, England) / Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
2024
AOU Città della Salute di Torino
Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; et alii...
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis. in Cancers / Cancers (Basel). 2023 Oct 17;15(20):5027. doi: 10.3390/cancers15205027.
2023
AOU Città della Salute di Torino
Palandri F; Palumbo GA; Bonifacio M; Elli EM; Tiribelli M; Auteri G; Trawinska MM; Polverelli N; Benevolo G; Tieghi A; Cavalca F; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Venturi M; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; et alii...
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib. in Blood cancer journal / Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6.
2023
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Semenzato GC; Cuneo A; Krampera M; Lemoli RM; Bartoletti D; Cattaneo D; Santoni E; D'Addio A; Ceglie S; Rindone G; Romagnoli AD; Crugnola M; Mazzoni C; Bocchia M; Miglino M; Mendicino F; Tatarelli C; Beggiato E; Cilloni D; Cavazzini F; Binotto G; Caocci G; Polverelli N; Iurlo A; Tieghi A; Tiribelli M; Bosi C; Rossi E; Trawinska MM; et alii...
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. in Cancer / Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.
2023
AOU Città della Salute di Torino
Cuneo A; Lemoli RM; Semenzato G; Cilloni D; Pane F; Krampera M; Cattaneo D; Isidori A; Scaffidi L; Venturi M; Biondo M; Pugliese N; Martino B; Bocchia M; Crugnola M; Bosi C; Miglino M; Cavazzini F; Binotto G; Beggiato E; Caocci G; Heidel FH; Tieghi A; Iurlo A; Benevolo G; Tiribelli M; Polverelli N; Trawinska MM; Elli EM; et alii...
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. in The Lancet. Oncology / Lancet Oncol. 2023 Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6.
2023
AOU Città della Salute di Torino
Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P; et alii...
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.
2023
AOU Città della Salute di Torino
Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F;
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.
2023
AOU Città della Salute di Torino
Zamagni E; Oliva S; Gay F; Capra A; Rota-Scalabrini D; D'Agostino M; Belotti A; Galli M; Racca M; Zambello R; Gamberi B; Albano D; Bertamini L; Versari A; Grasso M; Sgherza N; Priola C; Fioritoni F; Patriarca F; De Cicco G; Villanova T; Pascarella A; Zucchetta P; Tacchetti P; Fanti S; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. in Cancers / Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706.
2023
AOU Città della Salute di Torino
Palandri F; Rossi E; Auteri G; Breccia M; Paglia S; Benevolo G; Elli EM; Cavazzini F; Binotto G; Tieghi A; Tiribelli M; Heidel FH; Bonifacio M; Pugliese N; Caocci G; Crugnola M; Mendicino F; D'Addio A; Tomassetti S; Martino B; Polverelli N; Ceglie S; Mazzoni C; Mullai R; Ripamonti A; Garibaldi B; Pane F; Cuneo A; Krampera M; et alii...
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25.
2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Visco C; Corradini P; Passamonti F; Bertù L; Gherlinzoni F; Pagano L; Guidetti A; Cilloni D; Visani G; Federici AB; Tisi MC; Cudillo L; Galimberti S; Coviello E; Della Porta MG; Mohamed S; Mauro FR; Gentile M; Gambacorti-Passerini C; Massaia M; Bocchia M; Billio A; Cattaneo C; Derenzini E; Scattolin A; Marchesi F; Fracchiolla NS; Arcaini L; Trentin L; et alii...
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. in British journal of haematology / Br J Haematol. 2023 Aug;202(3):599-607. doi: 10.1111/bjh.18887. Epub 2023 May 24.
2023
AO Ordine Mauriziano
AOU Città della Salute di Torino
Martelli MP; Curti A; Papayannidis C; Cavo M; Cardinali V; Sciabolacci S; Forte D; Bandini L; Ottaviani E; Patuelli A; Zingarelli F; Ciruolo R; Nanni J; Cristiano G; Zannoni L; Cignetti A; Audisio E; Brunetti L; Sartor C;
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Sep;33(9):988. doi: 10.1016/j.annonc.2022.05.004. Epub 2022 Jul 6.
2022
AOU Città della Salute di Torino
Boccadoro M; Einsele H; Facon T; Goldschmidt H; Cavo M; Schjesvold F; Cook G; Delforge M; Hájek R; Zweegman S; Mateos MV; Terpos E; Moreau P; Dimopoulos MA; San-Miguel J; Sonneveld P; Mey U;
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. in The lancet. Healthy longevity / Lancet Healthy Longev. 2022 Sep;3(9):e628-e635. doi: 10.1016/S2666-7568(22)00172-6.
2022
AOU Città della Salute di Torino
Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M;
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
2022
AOU Città della Salute di Torino
Cook G; Larocca A; Hernández Rivas JM; Goldschmidt H; Kaiser MF; Cavo M; Zweegman S; Gay F; Dürig J; Mai EK; Capra A; Castellani G; Bonello F; van der Holt B; Salwender H; Bladé Creixenti J; Rocchi S; van de Donk NWCJ; Jackson G; Dall'Olio D; Mateos MV; Zamagni E; Waage A; Bertsch U; Lahuerta JJ; Wester R; Cairns DA; D'Agostino M; San-Miguel JF; et alii...
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. in Hematological oncology / Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1.
2022
AOU Città della Salute di Torino
Zamagni E; Bringhen S; Consoli U; Frigeri F; Pompa A; Tripepi G; Gamberi B; Gagliardi A; Gangemi D; Ballanti S; Martino M; Stocchi R; Cupelli L; Bonalumi A; Sgherza N; Vincelli D; Botta C; Mimmi S; Iaccino E; Vigna E; Mendicino F; Curci P; Uccello G; Criscuolo C; Belotti A; Cerchione C; Cascavilla N; Palumbo G; Pietrantuono G; et alii...
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. in HemaSphere / Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.
2022
AOU Città della Salute di Torino
Sonneveld P; Zweegman S; Cavo M; Nasserinejad K; Broijl A; Troia R; Pour L; Croockewit S; Corradini P; Patriarca F; Wu K; Droogendijk J; Bos G; Hajek R; Teresa Petrucci M; Ypma P; Zojer N; Minnema MC; Boccadoro M;
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. in Haematologica / Haematologica. 2022 Nov 1;107(11):2536-2547. doi: 10.3324/haematol.2022.280893.
2022
AOU Città della Salute di Torino
De Stefano V; Larocca A; Carpenedo M; Cavo M; Di Raimondo F; Falanga A; Offidani M; Petrucci MT; Ruggeri M; Santi RM; Barosi G;
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. in European journal of haematology / Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 2021 Nov 9.
2022
AOU Città della Salute di Torino
Musso M; De Stefano V; Musto P; Rizzello I; Barone M; Farina G; Reddiconto G; Cangialosi C; Pia Falcone A; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Bruzzese A; Botta C; Vigna E; Antonia Martino E; Mele G; Donatella Vincelli I; Tacchetti P; Catalano L; Ria R; Rossi E; Derudas D; Galli M; et alii...
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.
2022
AOU Città della Salute di Torino
Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. in Cancer / Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1.
2022
AOU Città della Salute di Torino
Palandri F; Bartoletti D; Iurlo A; Bonifacio M; Abruzzese E; Caocci G; Elli EM; Auteri G; Tiribelli M; Polverelli N; Miglino M; Heidel FH; Tieghi A; Benevolo G; Beggiato E; Fava C; Cavazzini F; Pugliese N; Binotto G; Bosi C; Martino B; Crugnola M; Ottaviani E; Micucci G; Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; et alii...
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.
2022
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Corradini P; Merli F; Passamonti F; Candoni A; Krampera M; Venditti A; Selleri C; Tosi P; Lanza F; Conconi A; La Barbera EO; Gambacorti-Passerini C; Visani G; Vallisa D; Rigacci L; Armiento D; Gherlinzoni F; Tafuri A; Galimberti S; Bocchia M; Corso A; Cilloni D; Cardinali V; Turrini M; Trentin L; Cuneo A; Della Porta M; Massaia M; Fracchiolla N; et alii...
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. in Blood advances / Blood Adv. 2022 Jan 11;6(1):87-99. doi: 10.1182/bloodadvances.2021004878.
2022
AOU Città della Salute di Torino
Ragaini S; Wagner S; Marconi G; Parisi S; Sartor C; Nanni J; Cristiano G; Talami A; Olivi M; Ocadlikova D; Ciciarello M; Corradi G; Ottaviani E; Papayannidis C; Paolini S; Vadakekolathu J; Cavo M; Rutella S; Curti A;
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):117. doi: 10.1016/j.annonc.2021.10.001. Epub 2021 Nov 29.
2022
AOU Città della Salute di Torino
Boccadoro M; Einsele H; Facon T; Goldschmidt H; Cavo M; Schjesvold F; Delforge M; Hájek R; Cook G; Zweegman S; Mateos MV; Terpos E; Moreau P; Dimopoulos MA; San-Miguel J; Sonneveld P; Mey U;
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. in British journal of haematology / Br J Haematol. 2022 Feb;196(3):639-648. doi: 10.1111/bjh.17887. Epub 2021 Oct 21.
2022
AOU Città della Salute di Torino
Laubach J; Nadeem O; Mazumder A; Raptis A; Rodriguez-Otero P; Oriol A; Alegre A; Cavo M; Maisel C; Mateos MV; Paner A; Bladé J; Touzeau C; Leleu X; Larocca A; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG;
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.
2022
AO Cuneo
AOU Città della Salute di Torino
Corradini P; Passamonti F; Antonio Grossi P; Bruno R; Pagano L; Luppi M; Busca A; Giuliani N; Corso A; Mohamed S; Tosi P; Giovanni Della Porta M; Lanza F; Rigacci L; Massimo Lemoli R; Venditti A; Tafuri A; Billio A; Gentile M; Falini B; Turrini M; Chiara Tisi M; Morotti A; Coviello E; Trentin L; Bocchia M; Galimberti S; Cuneo A; Musto P; et alii...
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. in Frontiers in oncology / Front Oncol. 2022 Mar 14;12:851864. doi: 10.3389/fonc.2022.851864. eCollection 2022.
2022
AOU Città della Salute di Torino
Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R;
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials. in Frontiers in oncology / Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022.
2022
AOU Città della Salute di Torino
De Stefano V; Musto P; Gamberi B; Curci P; Mimmi S; Rizzello I; Iaccino E; Barone M; Farina G; Reddiconto G; Cangialosi C; Falcone AP; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Botta C; Mendicino F; Bruzzese A; Martino EA; Vigna E; Mele G; Vincelli ID; Tacchetti P; Catalano L; et alii...
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14.
2021
AOU Città della Salute di Torino
Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; et alii...
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. in Haematologica / Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.
2021
AOU Città della Salute di Torino
Engelhardt M; Musto P; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS;
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. in Blood / Blood. 2021 Mar 4;137(9):1154-1165. doi: 10.1182/blood.2020008209.
2021
AOU Città della Salute di Torino
Anttila P; Capra M; Bringhen S; Dimopoulos M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R;
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9.
2021
AOU Città della Salute di Torino
Laubach JP; Moreb JS; Anderson KC; Raptis A; Mazumder A; Maisel C; Paner A; Alegre A; Hassoun H; Touzeau C; Hiemenz JW; Nadeem O; Leleu X; Rodriguez-Otero P; Cavo M; Bladé J; Larocca A; Oriol A; Richardson PG; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.
2021
AOU Città della Salute di Torino
Boccadoro M; Einsele H; Facon T; Goldschmidt H; Cavo M; Schjesvold F; Delforge M; Hájek R; Cook G; Zweegman S; Mateos MV; Terpos E; Moreau P; Dimopoulos MA; San-Miguel J; Sonneveld P; Mey U;
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
2021
AOU Città della Salute di Torino
Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. in Blood cancer journal / Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0.
2021
AOU Città della Salute di Torino
Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P;
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. in Leukemia / Leukemia. 2021 Jul;35(7):2102-2107. doi: 10.1038/s41375-020-01098-w. Epub 2020 Dec 1.
2021
AOU Città della Salute di Torino
Percesepe A; Rosti G; Papayannidis C; Gugliotta G; Castagnetti F; Capodanno I; D'Adda M; Crugnola M; Albano F; Lunghi F; Galimberti S; Pregno P; Bonifacio M; Iurlo A; Sorà F; Sica S; De Benedittis C; Bavaro L; Martelli M; Soverini S; Mignone F; Baccarani M; Martinelli G; Cavo M;
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. in Blood cancer journal / Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.
2021
AOU Città della Salute di Torino
Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; et alii...
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. in Haematologica / Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.
2021
AOU Città della Salute di Torino
Gentile M; Specchia G; Derudas D; Galli M; Botta C; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Attingenti E; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Musto P; Capalbo S; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; et alii...
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2021 Jan;35(1):31-44. doi: 10.1038/s41375-020-01016-0. Epub 2020 Aug 19.
2021
AOU Città della Salute di Torino
van de Donk N; Leleu X; Engelhardt M; Garderet L; Jackson G; Weisel K; Caers J; Delforge M; Mateos MV; Einsele H; Mohty M; Zojer N; Terpos E; Avet-Loiseau H; Gay F; Dimopoulos MA; Hajek R; Facon T; Driessen C; Zweegman S; Pawlyn C; San-Miguel J; Cavo M; Moreau P; Boccadoro M; Ludwig H; Goldschmidt H; Beksac M; Nijhof I; et alii...
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. in HemaSphere / Hemasphere. 2021 Feb 3;5(2):e528. doi: 10.1097/HS9.0000000000000528. eCollection 2021 Feb.
2021
AOU Città della Salute di Torino
Dimopoulos MA; Moreau P; Terpos E; Mateos MV; Zweegman S; Cook G; Delforge M; Hájek R; Schjesvold F; Cavo M; Goldschmidt H; Facon T; Einsele H; Boccadoro M; San-Miguel J; Sonneveld P; Mey U;
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. in Leukemia research / Leuk Res. 2021 Feb;101:106497. doi: 10.1016/j.leukres.2020.106497. Epub 2020 Dec 25.
2021
AOU Città della Salute di Torino
Paolini S; Curti A; Bonifazi F; Testoni N; Baldazzi C; Cristiano G; Raffini M; Fontana MC; Parisi S; Ottaviani E; Bochicchio MT; Sartor C; Abbenante MC; Ragaini S; Olivi M; Talami A; Bertamini L; Nanni J; Martinelli G; De Polo S; Marconi G; Cavo M; Papayannidis C;
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
2021
AO Cuneo
AOU Città della Salute di Torino
Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. in The Lancet. Haematology / Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
2021
AOU Città della Salute di Torino
Ludwig H; Sonneveld P; Facon T; San-Miguel J; Avet-Loiseau H; Mohty M; Mateos MV; Moreau P; Cavo M; Pawlyn C; Zweegman S; Engelhardt M; Driessen C; Cook G; Dimopoulos MA; Gay F; Einsele H; Delforge M; Caers J; Weisel K; Jackson G; Garderet L; van de Donk N; Leleu X; Goldschmidt H; Beksac M; Nijhof I; Schreder M; Abildgaard N; et alii...
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. in Blood / Blood. 2021 Aug 19;138(7):571-583. doi: 10.1182/blood.2021010735.
2021
AOU Città della Salute di Torino
AOU Novara
Rodeghiero F; Zaja F; De Stefano V; Mazzucconi MG; Cavo M; Carpenedo M; Carli G; Nicolosi D; Sutto E; Baldacci E; Auteri G; Borchiellini A; Giuffrida G; Oliva EN; Chiurazzi F; Caocci G; Cantoni S; Rivolti E; Consoli U; Patriarca A; Barcellini W; Lucchini E; Carrai V; Ferretti A; Ruggeri M; Vianelli N; Bartoletti D; Rossi E; Palandri F; et alii...
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. in Cancer / Cancer. 2021 Aug 1;127(15):2657-2665. doi: 10.1002/cncr.33541. Epub 2021 Apr 1.
2021
AOU Città della Salute di Torino
Cuneo A; Latagliata R; Pane F; Heidel FH; Bosi C; Crugnola M; Masselli E; Micucci G; Polverelli N; Scaffidi L; Stella R; Trawinska MM; Cattaneo D; Auteri G; Caocci G; Binotto G; Pugliese N; Abruzzese E; Iurlo A; Tieghi A; Cavazzini F; Martino B; Benevolo G; Elli EM; Bartoletti D; Breccia M; Tiribelli M; Palandri F; Krampera M; et alii...
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. in British journal of haematology / Br J Haematol. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16.
2021
AOU Città della Salute di Torino
Sezer O; Sonneveld P; Reece D; Rasche L; Moreau P; Mohty M; Merlini G; Lentzsch S; Mateos MV; Leleu X; Leal da Costa F; Kyle RA; Kröger N; Jurczyszyn A; Hungria V; Hájek R; Gay F; Gahrton G; Fernández de Larrea C; Engelhardt M; Dispenzieri A; Einsele H; Dimopoulos MA; Cavo M; Caers J; Badros A; Anderson KC; Van de Donk NWCJ; Zamagni E; et alii...
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. in Leukemia & lymphoma / Leuk Lymphoma. 2021 Aug;62(8):1897-1906. doi: 10.1080/10428194.2021.1897805. Epub 2021 Mar 18.
2021
AOU Città della Salute di Torino
Rocchi S; Mancuso K; Pantani L; Tacchetti P; Barbato S; Gozzetti A; Cea M; Morè S; D'Agostino M; Tosi P; Antonioli E; De Stefano V; Petrucci MT; Rivolti E; Dozza L; Cavo M; Rizzello I; De Cicco G; Fusco A; Zamagni E;
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):409-418. doi: 10.1002/hon.2843. Epub 2021 Mar 8.
2021
AOU Città della Salute di Torino
Lanza F; Krampera M; Cuneo A; Catani L; Carmosino I; Auteri G; Bossi E; Polverelli N; Caocci G; Bergamaschi M; Tieghi A; D'Addio A; Binotto G; Crugnola M; Bonifacio M; Cavazzini F; Heidel FH; Tiribelli M; Latagliata R; Bartoletti D; Elli EM; Benevolo G; Lemoli RM; Vianelli N; Breccia M; Palumbo GA; Cavo M; Palandri F;
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. in Biomedicines / Biomedicines. 2021 Apr 6;9(4):388. doi: 10.3390/biomedicines9040388.
2021
AOU Città della Salute di Torino
Fontana MC; Nanni J; Ghelli Luserna di Rorà A; Petracci E; Padella A; Ghetti M; Ferrari A; Marconi G; Soverini S; Iacobucci I; Papayannidis C; Curti A; Audisio E; Giannini MB; Rondoni M; Lanza F; Cavo M; Martinelli G; Simonetti G;
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. in Haematologica / Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428.
2021
AOU Città della Salute di Torino
Mina R; Bonello F; Petrucci MT; Liberati AM; Conticello C; Ballanti S; Musto P; Olivieri A; Benevolo G; Capra A; Gilestro M; Galieni P; Cavo M; Siniscalchi A; Palumbo A; Montefusco V; Gaidano G; Omedé P; Boccadoro M; Bringhen S;
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. in British journal of haematology / Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.
2021
AOU Città della Salute di Torino
Lemoli RM; Semenzato G; Krampera M; Cuneo A; Pane F; Catani L; Markovic U; Stella R; Trawinska MM; D'Amore F; Cattaneo D; Scaffidi L; Martino B; Gandolfi L; Latagliata R; Auteri G; Bartoletti D; Bosi C; Isidori A; Pugliese N; Crugnola M; Cavazzini F; Heidel FH; Binotto G; Bergamaschi M; D'Adda M; Caocci G; Tieghi A; Bonifacio M; et alii...
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
2020
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Corradini P; Pagano L; Bertù L; Corrao G; Grossi PA; Franchi M; Oberti M; Zappasodi P; Visco C; Armiento D; Pane F; Pinto A; Galieni P; Rigacci L; Candoni A; Venditti A; Fava C; Federici AB; Marchesi F; Musto P; Gentile M; Bocchia M; Di Renzo N; Olivieri A; Ferrandina C; Selleri C; Ortu La Barbera E; Luppi M; Scattolin AM; et alii...
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
2020
AOU Città della Salute di Torino
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. in European journal of haematology / Eur J Haematol. 2020 Jul;105(1):47-55. doi: 10.1111/ejh.13406. Epub 2020 Apr 7.
2020
AOU Città della Salute di Torino
Marconi G; Talami A; Abbenante MC; Sartor C; Parisi S; Nanni J; Bertamini L; Ragaini S; Olivi M; de Polo S; Cristiano G; Fontana MC; Bochicchio MT; Ottaviani E; Arpinati M; Sessa M; Baldazzi C; Caso L; Testoni N; Baccarani M; Bonifazi F; Martinelli G; Paolini S; Cavo M; Papayannidis C; Curti A;
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. in Haematologica / Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20.
2020
AOU Città della Salute di Torino
AOU Novara
Corradini P; Cavo M; Offidani M; Liberati AM; Sonneveld P; Hajek R; Nagler A; Ben-Yehuda D; Cascavilla N; Nozzoli C; Ballanti S; Galieni P; Patriarca F; Musto P; Musolino C; Ribolla R; De Paoli L; Di Raimondo F; Spada S; Boccadoro M; Gay F; Montefusco V;
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. in Hematological oncology / Hematol Oncol. 2020 Aug;38(3):372-380. doi: 10.1002/hon.2737. Epub 2020 Apr 20.
2020
AOU Città della Salute di Torino
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; et alii...
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. in Hematological oncology / Hematol Oncol. 2019 Oct;37(4):418-423. doi: 10.1002/hon.2619. Epub 2019 Jun 7.
2019
AOU Città della Salute di Torino
Krampera M; Cuneo A; Lemoli RM; Foà R; Cattaneo D; Auteri G; Bosi C; Cavazzini F; Heidel F; Crugnola M; Binotto G; Isidori A; Sgherza N; Tieghi A; Benevolo G; Tiribelli M; Martino B; Bergamaschi M; Bonifacio M; Elli E; Polverelli N; Iurlo A; Abruzzese E; Palumbo GA; Palandri F; Bartoletti D; Cavo M; Vianelli N; Breccia M; et alii...
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. in Cancer / Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.
2019
AOU Città della Salute di Torino
Sonneveld P; Cavo M; Palumbo A; Rocci A; Liberati AM; Offidani M; Gamberi B; Troia R; Bernardini A; Conticello C; Larocca A; Grammatico S; Saraci E; Gilestro M; Muccio VE; Spada S; Omedé P; Gambella M; Boccadoro M; Oliva S; Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; et alii...
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. in Current hematologic malignancy reports / Curr Hematol Malig Rep. 2019 Jun;14(3):187-196. doi: 10.1007/s11899-019-00507-x.
2019
AOU Città della Salute di Torino
Offidani M; Boccadoro M; Di Raimondo F; Petrucci MT; Tosi P; Cavo M;
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. in Journal of internal medicine / J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.
2019
AOU Città della Salute di Torino
Boccadoro M; Dimopoulos MA; Caers J; Gramatzki M; Auner HW; Ludwig H; Driessen C; Cavo M; Goldschmidt H; Terpos E; Zweegman S; Offidani M; Larocca A; Gay F; Wäsch R; Ferri C; D'Agostino M; Milan A; Bringhen S; Einsele H; Sonneveld P; Engelhardt M;
Insights on Multiple Myeloma Treatment Strategies. in HemaSphere / Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb.
2019
AOU Città della Salute di Torino
Plesner T; San-Miguel JF; O'Dwyer M; Mendeleeva L; Masszi T; Leiba M; Jamroziak K; Hansson M; Hájek R; Goldschmidt H; Geraldes C; Facon T; Dimopoulos MA; Delforge M; Cavo M; Boccadoro M; Bladé J; Beksac M; Bazarbachi A; Ludwig H; Mateos MV; Straka C; van de Donk NWCJ; Yong K; Zver S; Moreau P; Sonneveld P; Mateos MV; Ludwig H; et alii...
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. in Annals of hematology / Ann Hematol. 2019 Aug;98(8):1933-1936. doi: 10.1007/s00277-019-03727-6. Epub 2019 Jun 14.
2019
AOU Città della Salute di Torino
Martinelli V; Cavo M; Binotto G; Caocci G; Benevolo G; Latagliata R; Martino B; Bonifacio M; Tiribelli M; Scalzulli E; Rossi E; Pugliese N; Luciano L; Breccia M; Pane F; De Stefano V; Foà R; Palandri F;
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. in Haematologica / Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.
2019
AOU Città della Salute di Torino
Palumbo A; Di Raimondo F; Montefusco V; Di Toritto TC; Cavo M; Galieni P; Ponticelli E; Benevolo G; Spada S; Offidani M; Musto P; Ballanti S; Gaidano G; Petrucci MT; Mina R; Bringhen S; Boccadoro M; Larocca A;
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). in Haematologica / Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26.
2018
AOU Città della Salute di Torino
Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M; Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; et alii...
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study(?). in Seminars in hematology / Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
2018
AOU Città della Salute di Torino
Lemoli RM; Aversa F; Di Raimondo F; Cuneo A; Semenzato G; Russo D; Trawinska M; Soci F; Cattaneo D; Penna D; Scaffidi L; Ibatici A; Latagliata R; Auteri G; Binotto G; Bosi C; Cavazzini F; Crugnola M; Bergamaschi M; D'Adda M; Sgherza N; Martino B; Isidori A; Tieghi A; Bonifacio M; Tiribelli M; Abruzzese E; Breccia M; Benevolo G; et alii...
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Ju
2018
AOU Città della Salute di Torino
Borbényi Z; Louw V; Nemet D; Willenbacher W; Silva J; Pe?eli?nas V; Masliak Z; Salwender H; Laane E; Berthou C; Kochkareva Y; De Stefano V; Corso A; Durán MS; Stankovic S; Dimopoulos M; Legiec W; Bekadja MA; Beksac M; Lejniece S; Cavo M; Mateos MV; Terpos E; Mohty M; Abadi U; Pedersen RS; ?ernel? P; Potamianou A; Couturier C; et alii...
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. in British journal of haematology / Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.
2018
AOU Città della Salute di Torino
Palandri F; Catani L; Bonifacio M; Benevolo G; Heidel F; Palumbo GA; Crugnola M; Abruzzese E; Bartoletti D; Polverelli N; Bergamaschi M; Tiribelli M; Iurlo A; Breccia M; Cavazzini F; Tieghi A; Binotto G; Isidori A; Martino B; D'Adda M; Bosi C; Sabattini E; Vitolo U; Aversa F; Ibatici A; Lemoli RM; Sgherza N; Cuneo A; Martinelli G; et alii...
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. in Haematologica / Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.
2018
AOU Città della Salute di Torino
Caers J; Garderet L; Kortüm KM; O'Dwyer ME; van de Donk NWCJ; Binder M; Dold SM; Gay F; Corre J; Beguin Y; Ludwig H; Larocca A; Driessen C; Dimopoulos MA; Boccadoro M; Gramatzki M; Zweegman S; Einsele H; Cavo M; Goldschmidt H; Sonneveld P; Delforge M; Auner HW; Terpos E; Engelhardt M; Caers J; Garderet L; Kortüm KM; O'Dwyer ME; et alii...
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. in Leukemia research / Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5.
2018
AOU Città della Salute di Torino
Palandri F; Palumbo GA; Bonifacio M; Breccia M; Latagliata R; Martino B; Polverelli N; Abruzzese E; Tiribelli M; Nicolosi M; Bergamaschi M; Tieghi A; Iurlo A; Sgherza N; Cavazzini F; Isidori A; Binotto G; Ibatici A; Crugnola M; Heidel F; Bosi C; Bartoletti D; Auteri G; Catani L; Cuneo A; Aversa F; Semenzato G; Cavo M; Vianelli N; et alii...
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21
2018
AO Cuneo
AOU Città della Salute di Torino
Fanti S; Ghedini P; Cavo M; Gamberi B; Gay F; Patriarca F; Gallamini A; Bellò M; Bertone E; Rensi M; Bianchi A; Chauvie S; Nanni C; Versari A; Zamagni E;
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. in Health and quality of life outcomes / Health Qual Life Outcomes. 2018 Jun 18;16(1):127. doi: 10.1186/s12955-018-0953-4.
2018
AOU Città della Salute di Torino
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M;
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2.
2018
AOU Città della Salute di Torino
Beksac M; Waage A; van de Donk NWCJ; Weisel K; Kaiser M; Jackson G; Goldschmidt H; Leleu X; Cook G; Mateos MV; Garderet L; Zweegman S; Terpos E; San-Miguel JF; Dimopoulos MA; Cavo M; Mohty M; Hajek R; Boccadoro M; Avet-Loiseau H; Moreau P; Gay F; Einsele H; Facon T; Delforge M; Ludwig H; Mellqvist UH; Engelhardt M; Caers J; et alii...
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. in Haematologica / Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7.
2018
AOU Città della Salute di Torino
Cavo M; Kröger N; Boccadoro M; Dimopoulos M; Einsele H; Ludwig H; Straka C; Hajek R; Garderet L; Zamagni E; Oliva S; van de Donk N; Gramatzki M; Caers J; Auner HW; Giaccone L; Wäsch R; Terpos E; Engelhardt M; Gay F; Goldschmidt H; Bruno B; Sonneveld P;
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. in Hematological oncology / Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17.
2018
AOU Città della Salute di Torino
Scaffidi L; Cuneo A; Abruzzese E; Palumbo GA; Kallenberg L; Spinsanti M; Latagliata R; Martino B; Buccisano F; Heidel FH; Binotto G; Isidori A; Crugnola M; Polverelli N; Sgherza N; Bergamaschi M; Breccia M; Cavazzini F; Tieghi A; Benevolo G; Tiribelli M; Palandri F; Cavo M; Vianelli N; Bonifacio M;
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25.
2018
AOU Città della Salute di Torino
Einsele H; Boccadoro M; Dimopoulos MA; Offidani M; Gramatzki M; Auner HW; Caers J; Bringhen S; Ludwig H; Straka C; Cavo M; Gay F; Goldschmidt H; Scheubeck S; D'Agostino M; Wäsch R; Terpos E; Zweegman S; Dold SM; Larocca A; Sonneveld P; Engelhardt M; Larocca A; Dold SM; Zweegman S; Terpos E; Wäsch R; D'Agostino M; Scheubeck S; et alii...
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. in Hematological oncology / Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509.
2018
AOU Città della Salute di Torino
Polverelli N; Palumbo GA; Binotto G; Abruzzese E; Benevolo G; Bergamaschi M; Tieghi A; Bonifacio M; Breccia M; Catani L; Tiribelli M; D'Adda M; Sgherza N; Isidori A; Cavazzini F; Martino B; Latagliata R; Crugnola M; Heidel F; Bosi C; Ibatici A; Soci F; Penna D; Scaffidi L; Aversa F; Lemoli RM; Vitolo U; Cuneo A; Russo D; et alii...
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. in Haematologica / Haematologica. 2017 Sep;102(9):1530-1536. doi: 10.3324/haematol.2017.169532. Epub 2017 Jun 1.
2017
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Martinelli G; Cavo M; Foà R; Soverini S; Caracciolo C; Bonifacio M; Binotto G; Bigazzi C; Tiribelli M; Sorà F; La Barba G; Martino B; Stagno F; Cavazzini F; D'Adda M; Pregno P; Levato L; Intermesoli T; Abruzzese E; Albano F; Iurlo A; Breccia M; Castagnetti F; Gugliotta G; Pane F; Saglio G; Baccarani M; Rosti G; Gugliotta G; et alii...
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. in Oncotarget / Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.
2017
AOU Città della Salute di Torino
Palandri F; Palumbo GA; Bonifacio M; Tiribelli M; Benevolo G; Martino B; Abruzzese E; D'Adda M; Polverelli N; Bergamaschi M; Tieghi A; Cavazzini F; Ibatici A; Crugnola M; Bosi C; Latagliata R; Di Veroli A; Scaffidi L; de Marchi F; Cerqui E; Anaclerico B; De Matteis G; Spinsanti M; Sabattini E; Catani L; Aversa F; Di Raimondo F; Vitolo U; Lemoli RM; et alii...
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. in American journal of hematology / Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12.
2017
AOU Città della Salute di Torino
Vianelli N; Lewis RE; Martinelli G; Alimena G; Vitolo U; Merli F; Colafigli G; Campana A; Sollazzo D; Perricone M; Nicolosi M; Catani L; Godio L; Riminucci M; Latagliata R; Sabattini E; Martino B; Tieghi A; Breccia M; Benevolo G; Polverelli N; Cavo M; Palandri F;
Second primary malignancies in multiple myeloma: an overview and IMWG consensus. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606.
2017
AOU Città della Salute di Torino
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; et alii...
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. in Leukemia / Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353.
2017
AOU Città della Salute di Torino
Ludwig H; Delforge M; Facon T; Einsele H; Gay F; Moreau P; Avet-Loiseau H; Boccadoro M; Hajek R; Mohty M; Cavo M; Dimopoulos MA; San-Miguel JF; Terpos E; Zweegman S; Garderet L; Mateos MV; Cook G; Leleu X; Goldschmidt H; Jackson G; Kaiser M; Weisel K; van de Donk NWCJ; Waage A; Beksac M; Mellqvist UH; Engelhardt M; Caers J; et alii...
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. in American journal of hematology / Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.
2017
AO Ordine Mauriziano
AOU Città della Salute di Torino
Giovanni M; Cavo M; Bochicchio MT; Soverini S; Bocchia M; Gherlinzoni F; Fava C; Bonifacio M; Sica S; Tiribelli M; Usala E; Annunziata M; Pregno P; Orlandi E; Martino B; Cavazzini F; Rossi G; Rupoli S; Vigneri P; Abruzzese E; Albano F; Iurlo A; Levato L; Breccia M; Gugliotta G; Castagnetti F; Saglio G; Pane F; Baccarani M; et alii...
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.
2016
AOU Città della Salute di Torino
Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R; Vesole DH; Garderet L; Einsele H; Palumbo A; Cavo M; Richardson PG; Moreau P; San Miguel J; Rajkumar SV; Durie BG; Terpos E;
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). in Oncotarget / Oncotarget. 2016 Mar 1;7(9):9666-79. doi: 10.18632/oncotarget.5718.
2016
AOU Città della Salute di Torino
Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; Viganò CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M;
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.
2016
AO Cuneo
AOU Città della Salute di Torino
Fanti S; Gamberi B; Cavo M; Gay F; Patriarca F; Gallamini A; Rambaldi I; Rensi M; Bellò M; Bianchi A; Versari A; Chauvie S; Zamagni E; Nanni C;
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. in British journal of haematology / Br J Haematol. 2016 Jul;174(1):160-2. doi: 10.1111/bjh.13758. Epub 2015 Oct 28.
2016
AOU Città della Salute di Torino
Vianelli N; Cavo M; Alimena G; Vitolo U; Nicolino B; Breccia M; Polverelli N; Palandri F; Benevolo G;
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
2016
AOU Città della Salute di Torino
Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Bladé J; Mateos MV; Dimopoulos M; Kastritis E; Boccadoro M; Orlowski R; Goldschmidt H; Spencer A; Hou J; Chng WJ; Usmani SZ; Zamagni E; Shimizu K; Jagannath S; Johnsen HE; Terpos E; Reiman A; Kyle RA; Sonneveld P; Richardson PG; McCarthy P; et alii...
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. in Leukemia / Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.
2015
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Pane F; Martinelli G; Cavo M; Alimena G; Testoni N; Soverini S; Venturi C; Leoni P; Cavazzini F; Rossi G; Gherlinzoni F; Pregno P; Levato L; Intermesoli T; Martino B; Albano F; Abruzzese E; Iurlo A; Stagno F; Breccia M; Gugliotta G; Castagnetti F; Saglio G; Rosti G; Baccarani M;
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
2015
AOU Città della Salute di Torino
Palumbo A; Gay F; Cavallo F; Di Raimondo F; Larocca A; Hardan I; Nagler A; Petrucci MT; Hajek R; Pezzatti S; Delforge M; Patriarca F; Donato F; Cerrato C; Nozzoli C; Yu Z; Boccadifuoco L; Caravita T; Benevolo G; Guglielmelli T; Vincelli D; Jacques C; Dimopoulos MA; Ciccone G; Musto P; Corradini P; Cavo M; Boccadoro M;
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. in Bone marrow transplantation / Bone Marrow Transplant. 2015 May;50(5):673-8. doi: 10.1038/bmt.2014.322. Epub 2015 Feb 2.
2015
AOU Città della Salute di Torino
Brioli A; Perrone G; Patriarca F; Pezzi A; Nobile F; Ballerini F; Motta MR; Ronconi S; Tacchetti P; Catalano L; Zannetti BA; Rizzi S; Volpe S; Zamagni E; Liberati AM; Mancuso K; Boccadoro M; Davies FE; Morgan GJ; Palumbo A; Cavo M;
Differences among young adults, adults and elderly chronic myeloid leukemia patients. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jan;26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30.
2015
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Rosti G; Pane F; Saglio G; Martinelli G; Cavo M; Alimena G; de Vivo A; Tiribelli M; Gozzini A; Russo D; Bonifacio M; Gobbi M; Cuneo A; Stagno F; Pregno P; Martino B; Abruzzese E; Rossi G; Iurlo A; Specchia G; Levato L; Baccarani M; Breccia M; Gugliotta G; Castagnetti F;
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. in Stem cell research & therapy / Stem Cell Res Ther. 2015 Apr 17;6(1):64. doi: 10.1186/s13287-015-0033-1.
2015
AOU Città della Salute di Torino
Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M;
Autologous transplantation and maintenance therapy in multiple myeloma. in The New England journal of medicine / N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.
2014
AOU Città della Salute di Torino
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M;
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
2014
AOU Città della Salute di Torino
Rajkumar SV; Dimopoulos MA; Palumbo A; Blade J; Merlini G; Mateos MV; Kumar S; Hillengass J; Kastritis E; Richardson P; Landgren O; Paiva B; Dispenzieri A; Weiss B; LeLeu X; Zweegman S; Lonial S; Rosinol L; Zamagni E; Jagannath S; Sezer O; Kristinsson SY; Caers J; Usmani SZ; Lahuerta JJ; Johnsen HE; Beksac M; Cavo M; Goldschmidt H; et alii...
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.
2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Ria R; Offidani M; Gaidano G; Passera R; Nozzoli C; Guglielmelli T; Mina R; Morabito F; Marasca R; Omedé P; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Palumbo A; Petrucci MT; Musto P; Boccadoro M; et alii...
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. in The Lancet. Oncology / Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
2014
AOU Città della Salute di Torino
Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL;